Table 2.
Summary of the ongoing studies on GBM immunotherapies testing ICIs.
| Trial Name | Phase | Patients (N) | Treatment | Outcomes |
|---|---|---|---|---|
| NCT02311920 | I | 32 | Ipilimumab and/or nivolumab in combination with temozolomide | PFS and OS |
| NCT02336165 | II | 159 | Durvalumab monotherapy, with bevacizumab or with radiotherapy | OS and PFS |
| NCT02658981 | I | 63 | Anti-LAG3 or urelumab alone in combination with nivolumab | MTD |
| NCT03673787 | I/II | 87 | Atezolizumab in combination with ipatasertib | DLT |
| NCT03743662 | II | 94 | Nivolumab with radiation therapy and bevacizumab | T-lymphocyte density and safety |
| NCT03961971 | I | 15 | Anti-Tim-3 in combination with anti-PD-1 and stereotactic radiosurgery | Serious adverse events |
| NCT04145115 | II | 37 | Ipilimumab and nivolumab | DLT |
| NCT04396860 | II/III | 485 | Ipilimumab and nivolumab plus radiation therapy | Efficacy and safety |
| NCT04606316 | I | 60 | Nivolumab in combination with ipilimumab and surgery | Tumor infiltrating |
Abbreviations: DLT = dose-limiting toxicity, MTD = maximum tolerated dose, OS = overall survival, PFS = progression free survival.